Neuronetics, Inc. (STIM): Price and Financial Metrics


Neuronetics, Inc. (STIM): $6.20

-0.08 (-1.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

STIM POWR Grades

  • Sentiment is the dimension where STIM ranks best; there it ranks ahead of 98.09% of US stocks.
  • STIM's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
  • STIM's current lowest rank is in the Momentum metric (where it is better than 10.51% of US stocks).

STIM Stock Summary

  • NEURONETICS INC's market capitalization of $159,245,716 is ahead of only 24.17% of US-listed equities.
  • NEURONETICS INC's stock had its IPO on June 28, 2018, making it an older stock than merely 22.05% of US equities in our set.
  • Of note is the ratio of NEURONETICS INC's sales and general administrative expense to its total operating expenses; 72.97% of US stocks have a lower such ratio.
  • If you're looking for stocks that are quantitatively similar to NEURONETICS INC, a group of peers worth examining would be OYST, CDXC, NEO, MLSS, and PLAG.
  • Visit STIM's SEC page to see the company's official filings. To visit the company's web site, go to www.neurostar.com.

STIM Valuation Summary

  • In comparison to the median Healthcare stock, STIM's price/earnings ratio is 117.67% lower, now standing at -4.1.
  • STIM's price/sales ratio has moved down 8.8 over the prior 54 months.

Below are key valuation metrics over time for STIM.

Stock Date P/S P/B P/E EV/EBIT
STIM 2022-11-25 2.4 2.4 -4.1 -3.6
STIM 2022-11-23 2.3 2.2 -3.9 -3.3
STIM 2022-11-22 2.4 2.4 -4.1 -3.6
STIM 2022-11-21 2.4 2.3 -4.0 -3.5
STIM 2022-11-18 2.5 2.5 -4.3 -3.8
STIM 2022-11-17 2.5 2.5 -4.3 -3.7

STIM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • STIM has a Quality Grade of D, ranking ahead of 12.85% of graded US stocks.
  • STIM's asset turnover comes in at 0.477 -- ranking 99th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows STIM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.477 0.791 -0.385
2021-03-31 0.514 0.781 -0.493
2020-12-31 0.605 0.765 -0.637
2020-09-30 0.588 0.765 -0.893
2020-06-30 0.584 0.752 -0.892
2020-03-31 0.609 0.749 -0.766

STIM Price Target

For more insight on analysts targets of STIM, see our STIM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.50 Average Broker Recommendation 1.2 (Strong Buy)

STIM Stock Price Chart Interactive Chart >

Price chart for STIM

STIM Price/Volume Stats

Current price $6.20 52-week high $6.73
Prev. close $6.28 52-week low $1.98
Day low $6.14 Volume 541,700
Day high $6.73 Avg. volume 332,956
50-day MA $3.78 Dividend yield N/A
200-day MA $3.40 Market Cap 168.77M

Neuronetics, Inc. (STIM) Company Bio


Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company’s NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was founded in 2003 and is based in Malvern, Pennsylvania.


STIM Latest News Stream


Event/Time News Detail
Loading, please wait...

STIM Latest Social Stream


Loading social stream, please wait...

View Full STIM Social Stream

Latest STIM News From Around the Web

Below are the latest news stories about NEURONETICS INC that investors may wish to consider to help them evaluate STIM as an investment opportunity.

Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference

MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. The Company is scheduled to present at the conference at 9:30 am Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com . A repl...

GlobeNewswire | November 21, 2022

Neuronetics Inc. (STIM) produces promising results

As of Thursday, Neuronetics Inc.’s (NASDAQ:STIM) stock closed at $5.70, up from $5.00 the previous day. While Neuronetics Inc. has overperformed by 14.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, STIM rose by 31.34%, with highs and lows ranging from $5.01 to $1.98, whereas the […]

US Post News | November 18, 2022

Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations

Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy

GlobeNewswire | November 14, 2022

Neuronetics Announces NeuroStar Advanced Therapy for Mental Health System Innovations

Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy MALVERN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced

Wallstreet:Online | November 14, 2022

Neuronetics, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:STIM)

The following slide deck was published by Neuronetics, Inc.

Seeking Alpha | November 11, 2022

Read More 'STIM' Stories Here

STIM Price Returns

1-mo 80.23%
3-mo 78.16%
6-mo 117.54%
1-year 49.40%
3-year 36.56%
5-year N/A
YTD 39.01%
2021 -59.86%
2020 147.44%
2019 -76.80%
2018 N/A
2017 N/A

Continue Researching STIM

Here are a few links from around the web to help you further your research on Neuronetics Inc's stock as an investment opportunity:

Neuronetics Inc (STIM) Stock Price | Nasdaq
Neuronetics Inc (STIM) Stock Quote, History and News - Yahoo Finance
Neuronetics Inc (STIM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6264 seconds.